Artiva Biotherapeutics, Inc. (NASDAQ:ARTV – Get Free Report) Director Ra Capital Management, L.P. acquired 124,893 shares of Artiva Biotherapeutics stock in a transaction that occurred on Tuesday, June 16th. The shares were purchased at an average cost of $8.89 per share, for a total transaction of $1,110,298.77. Following the purchase, the director directly owned 16,763,043 shares in the company, valued at $149,023,452.27. The trade was a 0.75% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Ra Capital Management, L.P. also recently made the following trade(s):
- On Monday, June 15th, Ra Capital Management, L.P. acquired 15,414 shares of Artiva Biotherapeutics stock. The shares were purchased at an average price of $8.99 per share, with a total value of $138,571.86.
- On Friday, June 12th, Ra Capital Management, L.P. bought 391,019 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $8.57 per share, with a total value of $3,351,032.83.
- On Thursday, June 11th, Ra Capital Management, L.P. bought 548,580 shares of Artiva Biotherapeutics stock. The stock was purchased at an average price of $7.91 per share, for a total transaction of $4,339,267.80.
- On Wednesday, June 10th, Ra Capital Management, L.P. purchased 103 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $7.00 per share, for a total transaction of $721.00.
- On Tuesday, June 9th, Ra Capital Management, L.P. purchased 479,039 shares of Artiva Biotherapeutics stock. The shares were purchased at an average cost of $6.91 per share, for a total transaction of $3,310,159.49.
- On Monday, May 11th, Ra Capital Management, L.P. purchased 6,510,416 shares of Artiva Biotherapeutics stock. The stock was purchased at an average cost of $11.52 per share, with a total value of $74,999,992.32.
Artiva Biotherapeutics Stock Down 1.2%
ARTV opened at $9.82 on Friday. The stock has a market cap of $242.75 million, a P/E ratio of -2.77 and a beta of 2.38. Artiva Biotherapeutics, Inc. has a 12 month low of $1.47 and a 12 month high of $14.53. The company has a fifty day simple moving average of $9.13 and a 200 day simple moving average of $6.32.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently modified their holdings of the company. Citadel Advisors LLC boosted its position in Artiva Biotherapeutics by 419.3% during the 3rd quarter. Citadel Advisors LLC now owns 798,397 shares of the company’s stock worth $2,291,000 after acquiring an additional 644,658 shares during the last quarter. BNP Paribas Financial Markets raised its holdings in shares of Artiva Biotherapeutics by 14,463.5% in the third quarter. BNP Paribas Financial Markets now owns 118,547 shares of the company’s stock valued at $340,000 after purchasing an additional 117,733 shares during the last quarter. Marshall Wace LLP acquired a new stake in shares of Artiva Biotherapeutics in the fourth quarter valued at approximately $341,000. Jane Street Group LLC bought a new stake in shares of Artiva Biotherapeutics in the second quarter worth $67,000. Finally, Landscape Capital Management L.L.C. bought a new stake in shares of Artiva Biotherapeutics in the third quarter worth $112,000.
Wall Street Analysts Forecast Growth
Several equities analysts recently issued reports on the company. HC Wainwright boosted their price objective on Artiva Biotherapeutics from $15.00 to $35.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Wedbush raised their target price on shares of Artiva Biotherapeutics from $23.00 to $40.00 and gave the stock an “outperform” rating in a report on Monday, May 11th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Artiva Biotherapeutics in a research note on Friday, April 24th. Wall Street Zen cut shares of Artiva Biotherapeutics from a “hold” rating to a “sell” rating in a report on Sunday, May 17th. Finally, Needham & Company LLC reissued a “buy” rating and set a $41.00 price objective on shares of Artiva Biotherapeutics in a research report on Monday, June 8th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $39.00.
Read Our Latest Stock Report on ARTV
About Artiva Biotherapeutics
Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.
Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.
Featured Stories
- Five stocks we like better than Artiva Biotherapeutics
- Credo Technologies Accelerates AI—Its Stock Price Will Follow
- Qualcomm Goes All-In: The $10B Bet to Crush NVIDIA
- Jabil Just Gave Investors a Stronger Reason to Buy the Dip
- CarMax In Reverse? Why You Should Buy Now Before the Big Catalysts Emerge
Receive News & Ratings for Artiva Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artiva Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
